Social impact of brain fog and analysis of risk factors: Long COVID in Japanese population.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
04 Jul 2024
04 Jul 2024
Historique:
revised:
03
06
2024
received:
22
02
2024
accepted:
12
06
2024
medline:
4
7
2024
pubmed:
4
7
2024
entrez:
4
7
2024
Statut:
aheadofprint
Résumé
To reveal the clinical features and assess risk factors linked to brain fog and its societal implications, including labor productivity, providing valuable insights for the future care of individuals who have experienced coronavirus disease 2019 (COVID-19). We analyzed a comprehensive cohort dataset comprising 1,009 patients with COVID-19 admitted to Japanese hospitals. To assess brain fog, we analyzed patients who responded to a questionnaire indicating symptoms such as memory impairment and poor concentration. The prevalence of brain fog symptoms decreased 3 months posthospitalization but remained stable up to 12 months. Neurological symptoms such as taste and smell disorders and numbness at hospitalization correlated with a higher frequency of identifying brain fog as a long COVID manifestation. Our findings indicated that advanced age, female sex, a high body mass index, oxygen required during hospitalization, chronic obstructive pulmonary disease, asthma, and elevated C-reactive protein and elevated D-dimer levels were risk factors in patients exhibiting brain fog. Additionally, we demonstrated the negative impact of brain fog on labor productivity by presenteeism scores. This study clarified the clinical characteristics of patients experiencing brain fog as a long COVID manifestation, specifically emphasizing neurological symptoms during hospitalization and their correlation with brain fog. Additionally, the study identified associated risk factors for its onset and revealed that the emergence of brain fog was linked to a decline in labor productivity.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP 21fk0108431
Organisme : Japan Agency for Medical Research and Development
ID : JP 21fk0108553
Organisme : Japan Agency for Medical Research and Development
ID : JP 21fk0108563
Organisme : Japan Agency for Medical Research and Development
ID : JP 21fk0108573
Organisme : Japan Agency for Medical Research and Development
ID : JP 22fk0108510
Organisme : Japan Agency for Medical Research and Development
ID : JP 22fk0108513
Organisme : Japan Agency for Medical Research and Development
ID : JP 22fk0108573
Organisme : Japan Agency for Medical Research and Development
ID : JP 22wm0325031
Organisme : Japan Agency for Medical Research and Development
ID : JP20fk0108415
Organisme : Japan Agency for Medical Research and Development
ID : JP20fk0108452
Organisme : Japan Agency for Medical Research and Development
ID : JP20nk0101612
Organisme : Ministry of Health, Labour and Welfare
ID : 20CA2054
Organisme : Ministry of Health, Labour and Welfare
ID : JPMH21HA2011
Organisme : Ministry of Health, Labour and Welfare
ID : JPMH23HA2011
Organisme : Core Research for Evolutional Science and Technology
ID : JPMJCR20H2
Organisme : Precursory Research for Embryonic Science and Technology
ID : JPMJPR21R7
Informations de copyright
© 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Li X, Cui W, Zhang F. Who was the first doctor to report the COVID‐19 outbreak in Wuhan, China? J Nucl Med. 2020;61(6):782‐783.
COVID‐19 rapid guideline: managing the long‐term effects of COVID‐19. London. 2020.
Carfi A, Bernabei R, Landi F, Gemelli Against C‐P‐ACSG. Persistent symptoms in patients after acute COVID‐19. JAMA. 2020;324(6):603‐605.
Dennis A, Wamil M, Alberts J, et al. Multiorgan impairment in low‐risk individuals with post‐COVID‐19 syndrome: a prospective, community‐based study. BMJ Open. 2021;11(3):e048391.
Bowe B, Xie Y, Al‐Aly Z. Postacute sequelae of COVID‐19 at 2 years. Nat Med. 2023;29(9):2347‐2357.
Groff D, Sun A, Ssentongo AE, et al. Short‐term and long‐term rates of postacute sequelae of SARS‐CoV‐2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568.
Gentilotti E, Gorska A, Tami A, et al. Clinical phenotypes and quality of life to define post‐COVID‐19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort. EClinicalMedicine. 2023;62:102107.
Davis HE, McCorkell L, Vogel JM, Topol EJ. Author correction: Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(6):408.
McWhirter L, Smyth H, Hoeritzauer I, Couturier A, Stone J, Carson AJ. What is brain fog? J Neurol Neurosurg Psychiatry. 2023;94(4):321‐325.
Ishikura T, Nakano T, Kitano T, Tokuda T, Sumi‐Akamaru H, Naka T. Serum ferritin level during hospitalization is associated with brain fog after COVID‐19. Sci Rep. 2023;13(1):13095.
Lam GY, Damant RW, Ferrara G, et al. Characterizing long‐COVID brain fog: a retrospective cohort study. J Neurol. 2023;270(10):4640‐4646.
Taquet M, Skorniewska Z, Hampshire A, et al. Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID‐19 hospitalization. Nat Med. 2023;29(10):2498‐2508.
Lanz‐Luces JR, Aceituno H, Quiroz‐Bravo F, et al. Long‐lasting brain fog is related with severity clusters of symptoms in COVID‐19 patients. Rev Med Chile. 2022;150(11):1484‐1492.
Beretta S, Cristillo V, Camera G, et al. Incidence and Long‐term functional outcome of neurologic disorders in hospitalized patients with COVID‐19 infected with pre‐omicron variants. Neurology. 2023;101(9):e892‐e903.
Largent J, Xie Y, Knuth KB, et al. Cognitive and other neuropsychiatric symptoms in COVID‐19: analysis of person‐generated longitudinal health data from a community‐based registry. BMJ Open. 2023;13(6):e069118.
Imoto W, Yamada K, Kawai R, et al. A cross‐sectional, multicenter survey of the prevalence and risk factors for Long COVID. Sci Rep. 2022;12(1):22413.
Frontera JA, Yang D, Lewis A, et al. A prospective study of long‐term outcomes among hospitalized COVID‐19 patients with and without neurological complications. J Neurol Sci. 2021;426:117486.
Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in post‐COVID‐19 syndrome: a systematic review and meta‐analysis. Brain Behav Immun. 2022;101:93‐135.
Adingupu DD, Soroush A, Hansen A, Twomey R, Dunn JF. Brain hypoxia, neurocognitive impairment, and quality of life in people post‐COVID‐19. J Neurol. 2023;270(7):3303‐3314.
Zeng N, Zhao YM, Yan W, et al. A systematic review and meta‐analysis of long term physical and mental sequelae of COVID‐19 pandemic: call for research priority and action. Mol Psychiatry. 2023;28(1):423‐433.
Chudzik M, Babicki M, Kapusta J, et al. Long‐COVID clinical features and risk factors: a retrospective analysis of patients from the STOP‐COVID registry of the PoLoCOV study. Viruses. 2022;14(8):1755.
Asadi‐Pooya AA, Akbari A, Emami A, et al. Long COVID syndrome‐associated brain fog. J Med Virol. 2022;94(3):979‐984.
Johansson A, Mohamed MS, Moulin TC, Schioth HB. Neurological manifestations of COVID‐19: a comprehensive literature review and discussion of mechanisms. J Neuroimmunol. 2021;358:577658.
Stefano GB. Historical insight into infections and disorders associated with neurological and psychiatric sequelae similar to Long COVID. Med Sci Monit. 2021;27:e931447.
Ocon AJ. Caught in the thickness of brain fog: exploring the cognitive symptoms of chronic fatigue syndrome. Front Physiol. 2013;4:63.
Callan C, Ladds E, Husain L, Pattinson K, Greenhalgh T. I can't cope with multiple inputs': a qualitative study of the lived experience of ‘brain fog’ after COVID‐19. BMJ Open. 2022;12(2):e056366.
Bonilla H, Quach TC, Tiwari A, et al. Myalgic encephalomyelitis/chronic fatigue syndrome is common in post‐acute sequelae of SARS‐CoV‐2 infection (PASC): results from a post‐COVID‐19 multidisciplinary clinic. Front Neurol. 2023;14:1090747.
Nakagawara K, Namkoong H, Terai H, et al. Comprehensive and long‐term surveys of COVID‐19 sequelae in Japan, an ambidirectional multicentre cohort study: study protocol. BMJ Open Respir Res. 2021;8(1):e001015.
Terai H, Ishii M, Takemura R, et al. Comprehensive analysis of long COVID in a Japanese nationwide prospective cohort study. Respir Investig. 2023;61(6):802‐814.
Aronsson G, Gustafsson K, Dallner M. Sick but yet at work. An empirical study of sickness presenteeism. J Epidemiol Community Health. 2000;54(7):502‐509.
Suzuki T, Miyaki K, Sasaki Y, et al. Optimal cutoff values of WHO‐HPQ presenteeism scores by ROC analysis for preventing mental sickness absence in Japanese prospective cohort. PLoS One. 2014;9(10):e111191.
Kessler RC, Barber C, Beck A, et al. The World Health Organization health and work performance questionnaire (HPQ). J Occup Environ Med. 2003;45(2):156‐174.
Caspersen IH, Magnus P, Trogstad L. Excess risk and clusters of symptoms after COVID‐19 in a large Norwegian cohort. Eur J Epidemiol. 2022;37(5):539‐548.
Asadi‐Pooya AA, Shahisavandi M, Nemati H, et al. Long‐lasting COVID‐associated brain fog: a follow‐up study. Eur Neurol. 2023;86(3):166‐170.
Miskowiak KW, Johnsen S, Sattler SM, et al. Cognitive impairments four months after COVID‐19 hospital discharge: pattern, severity and association with illness variables. Eur Neuropsychopharmacol. 2021;46:39‐48.
Nordvig AS, Rajan M, Lau JD, et al. Brain fog in long COVID limits function and health status, independently of hospital severity and preexisting conditions. Front Neurol. 2023;14:1150096.
Zhou H, Lu S, Chen J, et al. The landscape of cognitive function in recovered COVID‐19 patients. J Psychiatr Res. 2020;129:98‐102.
Delgado‐Alonso C, Diez‐Cirarda M, Pagan J, et al. Unraveling brain fog in post‐COVID syndrome: relationship between subjective cognitive complaints and cognitive function, fatigue, and neuropsychiatric symptoms. Eur J Neurol. 2023 Oct 5.
Fernandez‐de‐Las‐Penas C, Cancela‐Cilleruelo I, Rodriguez‐Jimenez J, et al. Trajectory of post‐COVID brain fog, memory loss, and concentration loss in previously hospitalized COVID‐19 survivors: the LONG‐COVID‐EXP multicenter study. Front Hum Neurosci. 2023;17:1259660.
Kim Y, Bae S, Chang HH, Kim SW. Long COVID prevalence and impact on quality of life 2 years after acute COVID‐19. Sci Rep. 2023;13(1):11207.
Bauer L, Laksono BM, de Vrij FMS, Kushner SA, Harschnitz O, van Riel D. The neuroinvasiveness, neurotropism, and neurovirulence of SARS‐CoV‐2. Trends Neurosci. 2022;45(5):358‐368.
Apple AC, Oddi A, Peluso MJ, et al. Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID‐19. Ann Clin Transl Neurol. 2022;9(2):221‐226.
Greene C, Connolly R, Brennan D, et al. Blood‐brain barrier disruption and sustained systemic inflammation in individuals with long COVID‐associated cognitive impairment. Nat Neurosci. 2024;27(3):421‐432.
Scuffham PA, Vecchio N, Whiteford HA. Exploring the validity of HPQ‐based presenteeism measures to estimate productivity losses in the health and education sectors. Med Decis Mak. 2014;34(1):127‐137.
Chatys‐Bogacka Z, Mazurkiewicz I, Slowik J, et al. Brain fog and quality of life at work in non‐hospitalized patients after COVID‐19. Int J Environ Res Public Health. 2022;19(19):12816.